Free Trial
→ INSANE DRONE FOOTAGE (From Paradigm Press) (Ad)tc pixel Free AADI Stock Alerts

Aadi Bioscience (AADI) Financials

Aadi Bioscience logo
$2.97 -0.05 (-1.66%)
As of 10/14/2026
Compare
Annual Income Statements for Aadi Bioscience

Annual Income Statements for Aadi Bioscience

This table shows Aadi Bioscience's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -0.03 -21 -22 -10 -23 -4.47 -111 -61 -66 -64 -21
Consolidated Net Income / (Loss)		 -0.03 -17 -21 -10 -23 -3.48 -110 -61 -66 -64 -21
Net Income / (Loss) Continuing Operations		 -0.03 -17 -21 -10 -23 -3.48 -110 -61 -66 -64 -21
Total Pre-Tax Income 		-0.03 -17 -21 -10 -23 -3.48 -110 -61 -66 -64 -21
Total Operating Income		 -0.02 -17 -21 -11 -24 -2.55 -111 -63 -72 -67 -114
Total Gross Profit		 0.00 0.00 0.00 20 0.00 15 1.12 14 22 23 6.39
Total Revenue		 0.00 0.00 0.00 20 0.00 15 1.12 15 24 26 7.15
Operating Revenue		 - - - 20 0.00 15 1.12 15 24 26 7.15
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.34 2.81 3.02 0.76
Operating Cost of Revenue		 - - - - - - 0.00 1.34 2.81 3.02 0.76
Total Operating Expenses		 0.02 17 21 31 24 17 112 77 93 90 121
Selling, General & Admin Expense		 0.02 5.27 9.24 13 9.76 2.12 19 40 45 37 30
Research & Development Expense		 - 11 12 18 13 15 20 33 49 51 91
Restructuring Charge		 - - - - 1.86 - - - 0.00 2.64 0.00
Total Other Income / (Expense), net		 -0.01 -0.35 -0.01 0.78 1.17 -0.93 1.13 2.17 6.17 3.77 94
Interest Expense		 0.01 - - - - 0.82 0.47 0.23 0.23 0.15 0.00
Interest & Investment Income		 - -0.48 -0.11 0.78 1.03 0.04 0.01 2.40 6.40 3.93 6.23
Other Income / (Expense), net		 - 0.13 0.09 0.01 0.14 -0.15 1.59 0.00 -0.00 -0.00 88
Income Tax Expense		 - - - - - 0.00 0.00 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($0.01) ($24.52) ($1.03) ($0.31) ($0.57) ($1.76) ($12.41) ($2.69) ($2.44) ($2.36) ($0.33)
Weighted Average Basic Shares Outstanding		 5M 852.67K 21.67M 33.93M 40.59M 2.54M 8.92M 22.51M 26.92M 27.03M 61.89M
Diluted Earnings per Share		 ($0.01) ($24.52) ($1.03) ($0.31) ($0.57) ($1.76) ($12.41) ($2.69) ($2.44) ($2.36) ($0.33)
Weighted Average Diluted Shares Outstanding		 5M 852.67K 21.67M 33.93M 40.59M 2.54M 8.92M 22.51M 26.92M 27.03M 61.89M
Weighted Average Basic & Diluted Shares Outstanding		 5M 852.67K 21.67M 33.93M 40.59M 2.54M 8.92M 24.44M 24.55M 46.78M 47.20M

Quarterly Income Statements for Aadi Bioscience

This table shows Aadi Bioscience's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -16 -18 -15 -13 -18 73 -53 -18 -23 -22 -17
Consolidated Net Income / (Loss)		 -16 -18 -15 -13 -18 73 -53 -18 -23 -22 -17
Net Income / (Loss) Continuing Operations		 -16 -18 -15 -13 -18 73 -53 -18 -23 -22 -17
Total Pre-Tax Income 		-16 -18 -15 -13 -18 73 -53 -18 -23 -22 -17
Total Operating Income		 -18 -20 -16 -13 -19 -15 -55 -20 -25 -24 -18
Total Gross Profit		 5.40 4.70 5.40 6.41 6.45 6.39 0.00 0.00 - 0.00 0.00
Total Revenue		 6.33 5.35 6.18 7.21 7.24 7.15 0.00 0.00 - 0.00 0.00
Operating Revenue		 6.33 5.35 6.18 7.21 7.24 7.15 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 0.93 0.65 0.78 0.80 0.79 0.76 0.00 0.00 - 0.00 0.00
Operating Cost of Revenue		 0.93 0.65 0.78 0.80 0.79 0.76 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 23 24 21 20 25 22 55 20 25 24 18
Selling, General & Admin Expense		 10 11 7.89 7.19 11 13 5.94 5.20 5.87 6.29 5.22
Research & Development Expense		 13 14 13 10.00 14 8.79 49 14 19 17 13
Total Other Income / (Expense), net		 1.45 1.22 1.00 0.87 0.68 88 2.13 1.80 1.64 1.33 1.47
Interest & Investment Income		 1.50 1.28 1.06 0.91 0.68 0.79 1.98 1.85 1.61 1.33 1.48
Other Income / (Expense), net		 0.00 -0.00 -0.00 -0.00 - 87 0.16 -0.05 0.03 0.00 -0.01
Income Tax Expense		 - - - - - 0.00 0.00 - - 0.00 0.00
Basic Earnings per Share		 ($0.60) ($0.68) ($0.54) ($0.46) ($0.68) $1.84 ($0.76) ($0.26) ($1.15) ($0.32) ($0.20)
Weighted Average Basic Shares Outstanding		 26.92M 26.98M 27.01M 27.04M 27.03M 39.64M 69.08M 69.20M 61.89M 69.24M 82.89M
Diluted Earnings per Share		 ($0.60) ($0.68) ($0.54) ($0.46) ($0.68) $1.83 ($0.76) ($0.26) ($1.14) ($0.32) ($0.20)
Weighted Average Diluted Shares Outstanding		 26.92M 26.98M 27.01M 27.04M 27.03M 39.93M 69.08M 69.20M 61.89M 69.24M 82.89M
Weighted Average Basic & Diluted Shares Outstanding		 24.55M 24.55M 24.61M 24.65M 46.78M 47.11M 47.13M 47.13M 47.20M 49.45M 57.01M

Annual Cash Flow Statements for Aadi Bioscience

This table details how cash moves in and out of Aadi Bioscience's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.01 -3.53 19 42 -24 -12 145 -110 24 -34 8.83
Net Cash From Operating Activities		 -0.02 -16 -19 -5.81 -24 -13 -22 -50 -60 -60 -97
Net Cash From Continuing Operating Activities		 -0.02 -16 -19 -5.81 -24 -13 -22 -50 -60 -60 -97
Net Income / (Loss) Continuing Operations		 -0.03 -17 -21 -10 -23 -3.48 -110 -61 -66 -64 -21
Consolidated Net Income / (Loss)		 -0.03 -17 -21 -10 -23 -3.48 -110 -61 -66 -64 -21
Depreciation Expense		 - 0.07 0.05 0.05 0.08 0.01 0.11 0.16 0.17 0.19 0.08
Amortization Expense		 - 0.19 0.08 - - - 0.00 -1.22 -3.14 -1.30 -1.53
Non-Cash Adjustments To Reconcile Net Income		 0.00 0.49 0.89 2.99 1.68 1.27 75 14 12 11 -77
Changes in Operating Assets and Liabilities, net		 0.01 0.52 1.50 1.55 -2.34 -11 12 -1.82 -2.90 -5.54 1.93
Net Cash From Investing Activities		 0.00 -0.11 0.04 -0.04 -0.24 0.00 25 -133 83 25 12
Net Cash From Continuing Investing Activities		 0.00 -0.11 0.04 -0.04 -0.24 0.00 25 -133 83 25 12
Purchase of Property, Plant & Equipment		 - -0.11 -0.01 -0.04 -0.24 0.00 -0.05 -0.44 -3.97 -1.65 -0.55
Purchase of Investments		 - - - - - - 0.00 -145 -64 -36 -149
Divestitures		 - - - - - - - - - 0.00 101
Sale and/or Maturity of Investments		 - - 0.05 - - - 0.00 13 152 63 60
Net Cash From Financing Activities		 0.04 12 37 48 0.00 1.19 142 73 0.33 0.13 94
Net Cash From Continuing Financing Activities		 0.04 12 37 48 0.00 1.19 142 73 0.33 0.13 94
Repayment of Debt		 - -0.26 - - - 1.00 0.00 -0.34 -0.16 -0.02 -0.08
Repurchase of Common Equity		 - - -3.08 -3.50 0.00 - -9.62 -0.32 - 0.00 -5.63
Issuance of Common Equity		 - - 40 52 0.00 0.00 155 73 0.41 0.15 100
Other Financing Activities, net		 - 0.02 0.04 0.08 0.00 0.19 0.83 0.46 0.08 0.00 0.03
Cash Interest Paid		 - - - - - 0.00 0.02 0.23 0.23 0.21 0.00

Quarterly Cash Flow Statements for Aadi Bioscience

This table details how cash moves in and out of Aadi Bioscience's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -5.92 -9.11 -13 -11 -1.87 199 -83 -107 -0.36 -2.78 50
Net Cash From Operating Activities		 -9.64 -20 -9.16 -16 -15 -12 -53 -15 -17 -22 -15
Net Cash From Continuing Operating Activities		 -9.64 -20 -9.16 -16 -15 -12 -53 -15 -17 -22 -16
Net Income / (Loss) Continuing Operations		 -16 -18 -15 -13 -18 73 -53 -18 -23 -22 -17
Consolidated Net Income / (Loss)		 -16 -18 -15 -13 -18 73 -53 -18 -23 -22 -17
Depreciation Expense		 0.04 0.05 0.05 0.05 0.05 0.06 0.02 0.01 0.00 0.00 0.00
Amortization Expense		 -0.49 -0.42 -0.39 -0.31 -0.18 0.02 0.00 -0.72 -0.83 -0.35 -0.36
Non-Cash Adjustments To Reconcile Net Income		 2.72 3.76 2.95 2.65 1.42 -86 3.09 2.90 2.39 2.19 0.14
Changes in Operating Assets and Liabilities, net		 4.34 -4.75 2.81 -5.53 1.94 0.73 -3.45 0.19 4.46 -1.86 0.95
Net Cash From Investing Activities		 3.65 11 -3.57 5.09 13 115 -29 -92 17 19 -17
Net Cash From Continuing Investing Activities		 3.65 11 -3.57 5.09 13 115 -29 -92 17 19 -17
Purchase of Investments		 -14 -7.65 -19 -9.93 0.00 0.00 -32 -94 -23 -19 -51
Sale and/or Maturity of Investments		 18 19 16 15 13 15 3.39 2.00 40 39 34
Net Cash From Financing Activities		 0.08 -0.01 0.09 - 0.05 95 -0.85 - 0.03 0.00 82
Net Cash From Continuing Financing Activities		 0.08 -0.01 0.09 - 0.05 95 -0.85 - 0.03 0.00 82
Repurchase of Common Equity		 - 0.00 - - - -4.82 -0.80 - - 0.00 -5.65
Issuance of Common Equity		 0.11 0.00 0.09 - 0.05 100 0.02 - 0.03 0.00 88
Other Financing Activities, net		 - 0.00 - - - 0.02 0.01 - - 0.00 0.06

Annual Balance Sheets for Aadi Bioscience

This table presents Aadi Bioscience's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.02 2.40 21 64 40 19 158 184 132 70 151
Total Current Assets		 0.02 2.23 21 64 40 19 151 180 125 61 149
Cash & Equivalents		 0.02 1.61 20 63 39 4.46 149 39 63 29 38
Short-Term Investments		 - 0.05 - - - - 0.00 134 46 19 108
Prepaid Expenses		 - 0.35 0.31 0.75 0.31 0.08 2.28 3.75 3.83 2.84 3.32
Plant, Property, & Equipment, net		 0.00 0.15 0.11 0.10 0.16 0.02 0.06 0.51 4.80 6.85 0.00
Total Noncurrent Assets		 0.00 0.02 0.02 0.04 0.20 0.12 6.58 3.70 3.04 2.19 1.81
Other Noncurrent Operating Assets		 - 0.02 0.02 0.04 0.20 0.12 2.77 3.70 3.04 2.19 1.81
Total Liabilities & Shareholders' Equity		 0.02 2.40 21 64 40 19 158 184 132 70 151
Total Liabilities		 0.21 15 3.59 5.46 3.40 31 22 26 27 18 15
Total Current Liabilities		 0.21 15 3.59 5.46 3.33 30 15 19 26 17 15
Accounts Payable		 0.00 2.47 3.59 5.46 3.23 17 6.44 3.52 5.90 2.16 0.92
Accrued Expenses		 0.01 - - - - 4.10 8.70 15 14 15 14
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.07 1.20 6.23 7.02 0.83 0.77 0.00
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -0.19 -86 17 59 37 -12 136 158 105 52 136
Total Preferred & Common Equity		 -0.19 -86 17 59 37 -12 136 158 105 52 136
Preferred Stock		 0.00 - - - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -0.19 -86 17 59 37 -12 136 158 105 52 136
Common Stock		 0.05 0.00 126 178 179 20 279 362 374 385 489
Retained Earnings		 -0.24 -86 -109 -119 -142 -33 -143 -203 -269 -333 -353
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - 0.00 -0.12 0.03 0.02 0.12

Quarterly Balance Sheets for Aadi Bioscience

This table presents Aadi Bioscience's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 140 111 102 86 234 181 167 127 194
Total Current Assets		 133 103 93 77 233 179 165 126 192
Cash & Equivalents		 69 54 41 31 228 145 38 35 85
Short-Term Investments		 51 34 37 32 3.49 32 125 88 105
Prepaid Expenses		 4.22 3.43 2.42 2.69 1.55 1.47 2.44 2.51 2.43
Plant, Property, & Equipment, net		 3.60 5.69 6.00 5.98 0.03 0.01 0.00 0.00 0.00
Total Noncurrent Assets		 3.17 2.81 2.61 2.40 1.36 2.14 1.98 1.68 1.58
Other Noncurrent Operating Assets		 3.17 2.81 2.61 2.40 1.36 2.14 1.98 1.68 1.58
Total Liabilities & Shareholders' Equity		 140 111 102 86 234 181 167 127 194
Total Liabilities		 21 21 23 17 12 8.76 9.85 11 11
Total Current Liabilities		 21 20 22 16 12 8.76 9.85 11 11
Accounts Payable		 2.61 3.10 2.27 1.37 3.66 3.34 1.63 1.75 1.11
Accrued Expenses		 12 11 14 14 8.62 5.42 8.22 9.31 9.96
Total Noncurrent Liabilities		 0.95 0.74 0.68 1.02 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 118 90 79 69 222 172 157 116 183
Total Preferred & Common Equity		 118 90 79 69 222 172 157 116 183
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 118 90 79 69 222 172 157 116 183
Common Stock		 371 378 381 383 481 484 487 492 575
Retained Earnings		 -253 -287 -302 -314 -260 -312 -330 -375 -392
Accumulated Other Comprehensive Income / (Loss)		 -0.02 -0.01 -0.03 0.04 0.00 0.01 0.14 -0.02 -0.06

Annual Metrics And Ratios for Aadi Bioscience

This table displays calculated financial ratios and metrics derived from Aadi Bioscience's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 5,000,000.00 5,000,000.00 27,070,038.00 40,588,004.00 40,588,004.00 47,111,659.00 20,894,029.00 24,395,117.00 24,525,860.00 24,647,392.00 47,128,362.00
DEI Adjusted Shares Outstanding		 5,000,000.00 5,000,000.00 27,070,038.00 40,588,004.00 40,588,004.00 47,111,659.00 20,894,029.00 24,395,117.00 24,525,860.00 24,647,392.00 47,128,362.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.01 -4.18 -0.83 -0.26 -0.57 -0.09 -5.30 -2.48 -2.68 -2.58 -0.44
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% -92.32% 1,258.57% 60.06% 6.69% -72.50%
EBITDA Growth		 4.03% -70,503.09% -30.32% 47.43% -117.69% 88.88% -3,967.10% 41.81% -17.52% 8.45% 58.76%
EBIT Growth		 4.03% -71,626.10% -29.05% 47.52% -117.46% 88.88% -3,957.44% 42.83% -14.76% 6.22% 60.23%
NOPAT Growth		 4.03% -72,201.07% -28.59% 47.72% -118.62% 89.57% -4,263.16% 43.64% -14.76% 6.22% -69.59%
Net Income Growth		 -2.08% -53,918.80% -26.01% 51.42% -123.83% 85.05% -3,065.32% 45.03% -8.68% 3.15% 67.66%
EPS Growth		 0.00% -245,100.00% 95.80% 69.90% -83.87% -208.77% -605.11% 78.32% 9.29% 3.28% 86.02%
Operating Cash Flow Growth		 -35.67% -72,220.53% -20.14% 69.24% -310.68% 46.75% -76.55% -121.38% -20.19% 0.19% -63.62%
Free Cash Flow Firm Growth		 -68.01% -66,797.00% -39.86% 51.66% -184.27% 115.64% -2,514.91% 41.30% -44.01% 7.84% -16.65%
Invested Capital Growth		 -11.25% -13,688.66% -63.15% -39.55% 49.61% -239.64% -86.25% -12.71% 74.26% 243.59% -279.09%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.01% -100.00% -4.27% 310.92% 38.47% 4.73% 3.64% -50.33%
EBITDA Q/Q Growth		 0.64% -21.78% -16.98% -30.05% 15.26% -32.90% -10.73% -0.91% -2.33% -1.38% -30.49%
EBIT Q/Q Growth		 0.64% -23.72% -16.39% -29.88% 15.19% -31.41% -10.80% 0.82% -3.28% -1.87% -28.27%
NOPAT Q/Q Growth		 0.64% -24.71% -16.21% -29.96% 14.69% -16.97% -10.88% 0.75% -3.22% -1.86% -5.47%
Net Income Q/Q Growth		 -0.57% -26.01% -14.54% -28.15% 14.89% -75.59% -10.04% 3.32% -3.72% -3.25% -31.87%
EPS Q/Q Growth		 0.00% -22.17% 82.54% -255.00% -1.79% -45.45% 1.35% 0.37% -5.17% -3.51% -353.85%
Operating Cash Flow Q/Q Growth		 31.22% -23.97% -9.07% -37.12% 5.24% 11.13% -68.98% 2.20% 2.72% -9.99% -2.29%
Free Cash Flow Firm Q/Q Growth		 39.83% -6.27% -21.46% -29.10% 7.75% 189.52% -10.15% -20.79% 1.07% -4.41% -1.88%
Invested Capital Q/Q Growth		 -120.52% -32,693.38% -93.27% -72.37% -18.75% -5,248.61% -168.12% -2.04% -220.46% -16.13% -72.89%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 100.00% 0.00% 100.00% 100.00% 91.23% 88.47% 88.36% 89.36%
EBITDA Margin		 0.00% 0.00% 0.00% -55.21% 0.00% -18.47% -9,779.20% -418.88% -307.55% -263.90% -395.73%
Operating Margin		 0.00% 0.00% 0.00% -55.47% 0.00% -17.48% -9,930.09% -411.94% -295.36% -259.62% -1,601.12%
EBIT Margin		 0.00% 0.00% 0.00% -55.44% 0.00% -18.53% -9,788.57% -411.94% -295.37% -259.64% -375.47%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -51.58% 0.00% -23.85% -9,829.46% -397.69% -270.04% -245.13% -288.26%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.06% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 136.66% 102.92% 100.50% 93.04% 95.76% 128.65% 100.42% 96.54% 91.42% 94.41% 76.77%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,935.96% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,914.86% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5,855.18% 0.00%
Return on Equity (ROE)		 18.41% 268.57% -860.37% -27.32% -48.89% -28.86% -177.60% -41.06% -49.90% -80.79% -21.82%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,070.63% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -26.25% 0.00% -9.20% -124.06% -36.64% -45.43% -66.55% -24.26%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -24.42% 0.00% -11.84% -124.58% -35.37% -41.54% -62.83% -18.63%
Return on Common Equity (ROCE)		 18.41% 1,834.88% 11,895.85% -27.32% -48.89% -28.86% -177.60% -41.06% -49.90% -80.79% -21.82%
Return on Equity Simple (ROE_SIMPLE)		 16.86% 19.70% -122.74% -17.72% -63.69% 27.98% -80.71% -38.21% -62.52% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.02 -12 -15 -7.83 -17 -1.78 -78 -44 -50 -47 -80
NOPAT Margin		 0.00% 0.00% 0.00% -38.83% 0.00% -12.24% -6,951.06% -288.36% -206.75% -181.74% -1,120.78%
Net Nonoperating Expense Percent (NNEP)		 9.66% 97.97% -134.81% -6.20% -12.18% -10.31% -44.99% -10.35% -10.95% -21.10% 61.66%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -47.87% -89.98% -58.75%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8.77% 11.53% 11.64% 10.64%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 66.90% 0.00% 14.55% 1,652.77% 264.04% 182.92% 141.43% 417.38%
R&D to Revenue		 0.00% 0.00% 0.00% 88.57% 0.00% 102.94% 1,756.25% 214.66% 200.91% 196.40% 1,273.10%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 155.47% 0.00% 117.48% 10,030.09% 503.17% 383.83% 347.99% 1,690.48%
Earnings before Interest and Taxes (EBIT)		 -0.02 -17 -21 -11 -24 -2.70 -110 -63 -72 -67 -27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.02 -16 -21 -11 -24 -2.69 -110 -64 -75 -69 -28
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 1.18 0.69 0.00 3.70 1.98 0.47 1.48 0.84
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 1.18 0.69 0.00 3.81 1.98 0.47 1.48 0.84
Price to Revenue (P/Rev)		 0.00 0.00 0.00 3.42 0.00 3.17 450.53 20.57 2.03 2.99 15.96
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.82 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.32 0.00 3.56 317.50 9.23 0.00 1.17 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 17.38 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.86 -0.99 0.00 0.00 0.00 -0.81 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 -0.09 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.93 -0.86 -1.92 -1.09 -1.06 -1.36 -1.16 -1.09 -1.07 -0.99 -1.02
Leverage Ratio		 -0.07 -0.19 4.71 1.12 1.09 2.44 1.43 1.16 1.20 1.29 1.17
Compound Leverage Factor		 -0.10 -0.20 4.73 1.04 1.05 3.14 1.43 1.12 1.10 1.21 0.90
Debt to Total Capital		 -604.21% -16,717.93% 0.00% 0.00% 0.00% -440.29% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 -604.21% -16,717.93% 0.00% 0.00% 0.00% -392.39% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% -47.89% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% -0.04% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% -99,549.06% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 704.21% 116,366.99% 100.00% 100.00% 100.00% 540.33% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -6.95 -0.76 0.00 0.00 0.00 -3.76 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 -6.15 -0.66 0.00 0.00 0.00 -2.11 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.41 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -9.94 -1.06 0.00 0.00 0.00 -5.68 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 -8.78 -0.92 0.00 0.00 0.00 -3.18 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.62 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 5.82 -1.44 -1.96 11.56 5.73 -2.47 -6.05 1.96
Noncontrolling Interest Sharing Ratio		 0.00% -583.19% 1,482.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.09 0.15 5.82 11.73 11.87 0.62 9.90 9.56 4.72 3.59 10.26
Quick Ratio		 0.09 0.11 5.64 11.47 11.56 0.62 9.76 9.26 4.33 3.11 10.03
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.01 -9.92 -14 -6.71 -19 2.98 -72 -42 -61 -56 -65
Operating Cash Flow to CapEx		 0.00% -13,873.40% -212,269.95% -15,319.81% -10,066.39% 0.00% -48,745.65% -11,180.18% -1,502.09% -3,600.36% -17,650.91%
Free Cash Flow to Firm to Interest Expense		 -1.76 0.00 0.00 0.00 0.00 3.66 -153.57 -183.82 -263.57 -364.36 0.00
Operating Cash Flow to Interest Expense		 -2.58 0.00 0.00 0.00 0.00 -15.58 -47.81 -215.83 -258.28 -386.69 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -2.58 0.00 0.00 0.00 0.00 -15.58 -47.91 -217.76 -275.48 -397.43 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.47 0.00 0.50 0.01 0.09 0.15 0.26 0.06
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.63 4.56 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.68 0.52 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 196.02 0.00 157.46 28.72 53.86 9.17 4.46 2.09
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.27 0.60 0.75 0.49
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 55.08 80.01 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 538.47 708.39 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,361.30 611.82 486.24 738.64
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,361.30 -18.27 302.16 -738.64
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.01 -1.73 -2.83 -3.95 -1.99 -6.76 -13 -14 -3.65 5.24 -9.39
Invested Capital Turnover		 0.00 0.00 0.00 -5.95 0.00 -3.33 -0.12 -1.14 -2.73 32.66 -3.45
Increase / (Decrease) in Invested Capital		 -0.00 -1.72 -1.09 -1.12 1.96 -4.77 -5.83 -1.60 11 8.89 -15
Enterprise Value (EV)		 0.00 0.00 0.00 6.39 -13 52 356 140 -59 31 -32
Market Capitalization		 0.00 0.00 0.00 69 25 46 505 313 50 78 114
Book Value per Share		 ($0.04) ($17.24) $0.64 $1.45 $0.90 ($0.26) $6.53 $6.49 $4.29 $2.13 $2.89
Tangible Book Value per Share		 ($0.04) ($17.24) $0.64 $1.45 $0.90 ($0.26) $6.35 $6.49 $4.29 $2.13 $2.89
Total Capital		 -0.03 -0.07 17 59 37 -2.30 136 158 105 52 136
Total Debt		 0.16 12 0.00 0.00 0.00 10 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 1.10 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.14 11 -20 -63 -39 5.68 -149 -173 -109 -47 -146
Capital Expenditures (CapEx)		 0.00 0.11 0.01 0.04 0.24 0.00 0.05 0.44 3.97 1.65 0.55
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.05 -1.90 -2.96 -4.09 -2.29 -6.80 -13 -11 -11 -3.02 -11
Debt-free Net Working Capital (DFNWC)		 -0.03 -0.24 17 59 36 -2.34 136 161 98 44 134
Net Working Capital (NWC)		 -0.19 -13 17 59 36 -11 136 161 98 44 134
Net Nonoperating Expense (NNE)		 0.02 5.34 6.43 2.57 6.16 1.69 32 17 15 16 -59
Net Nonoperating Obligations (NNO)		 0.17 11 -20 -63 -39 5.68 -149 -173 -109 -47 -146
Total Depreciation and Amortization (D&A)		 0.00 0.26 0.13 0.05 0.08 0.01 0.11 -1.06 -2.97 -1.11 -1.45
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -20.27% 0.00% -46.63% -1,159.82% -74.70% -43.75% -11.64% -156.80%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 290.35% 0.00% -16.08% 12,142.77% 1,059.37% 403.18% 170.16% 1,882.35%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 290.35% 0.00% -78.00% 12,142.77% 1,059.37% 403.18% 170.16% 1,882.35%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.01) ($0.01) ($1.03) ($0.31) ($0.57) ($0.10) ($12.41) ($2.69) ($2.44) ($2.36) ($0.33)
Adjusted Weighted Average Basic Shares Outstanding		 5M 5M 27.14M 40.59M 40.59M 47.31M 20.93M 22.51M 26.92M 27.03M 61.89M
Adjusted Diluted Earnings per Share		 ($0.01) ($0.01) ($1.03) ($0.31) ($0.57) ($0.10) ($12.41) ($2.69) ($2.44) ($2.36) ($0.33)
Adjusted Weighted Average Diluted Shares Outstanding		 5M 5M 27.14M 40.59M 40.59M 47.31M 20.93M 22.51M 26.92M 27.03M 61.89M
Adjusted Basic & Diluted Earnings per Share		 ($0.01) ($0.01) ($1.03) ($0.31) ($0.57) ($0.10) ($12.41) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5M 5M 21.67M 33.93M 40.59M 42.62M 8.92M 24.44M 24.55M 46.78M 47.20M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.02 -12 -15 -7.83 -16 -1.78 -26 -41 -50 -45 -80
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -38.83% 0.00% -12.24% -2,316.31% -271.23% -206.75% -174.63% -1,120.78%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -51.58% 0.00% -23.84% -9,829.29% -397.69% -270.04% -245.13% -288.26%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -2.73 0.00 0.00 0.00 0.00 -3.32 -233.76 -272.53 -311.40 -438.06 0.00
NOPAT to Interest Expense		 -1.91 0.00 0.00 0.00 0.00 -2.19 -166.00 -190.77 -217.98 -306.63 0.00
EBIT Less CapEx to Interest Expense		 -2.73 0.00 0.00 0.00 0.00 -3.32 -233.86 -274.46 -328.60 -448.81 0.00
NOPAT Less CapEx to Interest Expense		 -1.91 0.00 0.00 0.00 0.00 -2.19 -166.09 -192.70 -235.17 -317.37 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4.01% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -14.41% -33.69% 0.00% 0.00% -12.74% -0.53% 0.00% 0.00% -27.31%

Quarterly Metrics And Ratios for Aadi Bioscience

This table displays calculated financial ratios and metrics derived from Aadi Bioscience's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 24,525,860.00 24,554,205.00 24,554,205.00 24,614,834.00 24,647,392.00 46,784,618.00 47,109,293.00 47,128,362.00 47,128,362.00 47,196,564.00 49,452,463.00
DEI Adjusted Shares Outstanding		 24,525,860.00 24,554,205.00 24,554,205.00 24,614,834.00 24,647,392.00 46,784,618.00 47,109,293.00 47,128,362.00 47,128,362.00 47,196,564.00 49,452,463.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.66 -0.74 -0.59 -0.51 -0.74 1.56 -1.12 -0.38 -0.49 -0.47 -0.34
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 21.03% -8.76% -0.37% 21.03% 14.43% 33.48% -100.00% -100.00% 0.00% -100.00% 0.00%
EBITDA Growth		 -10.37% -10.55% 21.81% 25.65% -5.13% 463.60% -242.73% -48.49% -34.62% -133.01% 66.15%
EBIT Growth		 -14.80% -15.98% 20.27% 24.85% -6.98% 470.14% -250.28% -46.09% -31.20% -132.57% 66.82%
NOPAT Growth		 -14.50% -15.97% 20.27% 24.85% -6.97% -11.42% -251.32% -45.72% -31.34% -8.20% 66.92%
Net Income Growth		 -16.93% -20.14% 18.85% 23.04% -12.32% 499.23% -260.80% -41.45% -27.24% -130.40% 68.37%
EPS Growth		 -25.00% -19.30% 19.40% 23.33% -13.33% 369.12% -40.74% 43.48% -67.65% -117.49% 73.68%
Operating Cash Flow Growth		 14.73% 7.78% 45.36% -31.26% -56.09% 39.63% -478.32% 1.97% -14.49% -87.19% 72.56%
Free Cash Flow Firm Growth		 -148.43% -78.11% 27.78% 33.57% 3.39% 82.43% -125.78% 88.05% 87.39% -412.35% 67.38%
Invested Capital Growth		 74.26% 142.19% 106.43% 648.64% 243.59% -526.40% -2,402.24% -186.88% -279.09% 26.42% -37.46%
Revenue Q/Q Growth		 6.16% -15.38% 15.43% 16.72% 0.37% -1.30% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 1.30% -9.54% 19.92% 14.12% -39.55% 478.84% -175.48% 62.79% -26.51% 7.10% 22.60%
EBIT Q/Q Growth		 0.77% -10.17% 20.13% 13.94% -41.26% 481.15% -175.59% 64.11% -26.87% 5.39% 22.99%
NOPAT Q/Q Growth		 0.76% -10.15% 20.13% 13.93% -41.27% -14.73% -151.84% 64.30% -27.33% 5.48% 23.01%
Net Income Q/Q Growth		 0.20% -12.42% 20.26% 13.97% -45.65% 499.58% -172.06% 66.27% -31.02% 4.55% 25.02%
EPS Q/Q Growth		 0.00% -13.33% 20.59% 14.81% -47.83% 369.12% -141.53% 65.79% -338.46% 71.93% 37.50%
Operating Cash Flow Q/Q Growth		 19.30% -103.78% 53.41% -71.31% 4.04% 21.19% -346.37% 70.96% -12.07% -28.86% 34.58%
Free Cash Flow Firm Q/Q Growth		 9.20% 8.27% 30.58% -14.90% -32.06% 83.32% -792.21% 93.92% -39.40% -577.60% 43.20%
Invested Capital Q/Q Growth		 -220.46% 159.97% -89.81% 2,702.24% -16.13% -278.10% 45.00% -5.75% -72.89% 26.83% -2.75%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 85.35% 87.82% 87.41% 88.85% 89.09% 89.36% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -286.97% -371.47% -257.71% -189.63% -263.64% 1,011.91% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -280.02% -364.51% -252.21% -185.98% -261.76% -212.99% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -279.99% -364.52% -252.24% -186.00% -261.76% 1,010.85% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -257.18% -341.66% -236.01% -173.96% -252.42% 1,021.92% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 91.85% 93.73% 93.56% 93.53% 96.43% 101.10% 96.38% 90.56% 93.52% 94.35% 91.86%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -1,277.41% -5,984.87% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -1,273.94% -5,978.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 1,239.14% 5,918.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -49.90% -58.22% -62.26% -38.27% -66.74% 17.69% -8.31% 0.00% -21.82% -68.54% -44.98%
Cash Return on Invested Capital (CROIC)		 0.00% -2,723.21% -23,836.01% -860.04% -1,070.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -43.07% -61.69% -47.52% -41.38% -67.09% 162.73% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -39.56% -57.82% -44.46% -38.70% -64.70% 164.51% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -49.90% -58.22% -62.26% -38.27% -66.74% 17.69% -8.31% 0.00% -21.82% -68.54% -44.98%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -76.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -12 -14 -11 -9.39 -13 -15 -38 -14 -17 -16 -13
NOPAT Margin		 -196.01% -255.15% -176.55% -130.19% -183.23% -212.99% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.75% -3.87% -3.44% -3.47% -6.42% 55.26% -11.17% -3.61% -6.04% -3.24% -2.16%
Return On Investment Capital (ROIC_SIMPLE)		 -11.79% -15.10% -13.85% -13.63% -25.28% -6.86% -22.27% -8.71% -12.78% -14.17% -6.93%
Cost of Revenue to Revenue		 14.65% 12.18% 12.59% 11.15% 10.91% 10.64% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 163.53% 198.39% 127.72% 99.64% 152.66% 179.36% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 201.83% 253.93% 211.90% 138.62% 198.19% 123.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 365.37% 452.33% 339.62% 274.83% 350.85% 302.35% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -18 -20 -16 -13 -19 72 -55 -20 -25 -24 -18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -20 -16 -14 -19 72 -55 -20 -26 -24 -18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.47 0.64 0.46 0.74 1.48 0.38 0.51 0.57 0.84 1.40 1.24
Price to Tangible Book Value (P/TBV)		 0.47 0.64 0.46 0.74 1.48 0.38 0.51 0.57 0.84 1.40 1.24
Price to Revenue (P/Rev)		 2.03 2.41 1.51 2.02 2.99 3.00 4.08 6.23 15.96 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 3.02 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 33.16% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 5.82 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 1.17 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.07 -1.01 -1.02 -0.97 -0.99 -1.02 -1.02 -1.00 -1.02 -1.05 -1.03
Leverage Ratio		 1.20 1.19 1.20 1.20 1.29 1.11 1.13 1.12 1.17 1.07 1.06
Compound Leverage Factor		 1.10 1.12 1.13 1.13 1.24 1.12 1.09 1.01 1.10 1.01 0.97
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -1.12 -1.42 -2.65 -2.69 -3.77 4.78 3.87 3.50 2.01 5.18 10.26
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.72 5.16 4.20 4.89 3.59 18.95 20.41 16.76 10.26 11.36 17.38
Quick Ratio		 4.33 4.69 3.81 4.37 3.11 18.83 20.24 16.51 10.03 11.13 17.16
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -23 -21 -15 -17 -22 -3.70 -33 -2.00 -2.79 -19 -11
Operating Cash Flow to CapEx		 -1,181.86% -2,659.40% -1,692.61% -8,344.15% -8,093.01% -2,153.18% -5,295,700.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -402.31 -362.68 -251.76 -441.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -169.19 -338.84 -157.88 -412.82 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -183.51 -351.59 -167.21 -417.76 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.15 0.17 0.19 0.22 0.26 0.16 0.15 0.11 0.06 0.00 0.00
Accounts Receivable Turnover		 6.63 4.54 4.96 4.09 4.56 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.68 0.60 0.64 0.70 0.52 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 9.17 6.03 5.29 5.23 4.46 9.73 7.18 4.81 2.09 0.00 0.00
Accounts Payable Turnover		 0.60 0.61 1.18 1.59 0.75 0.93 0.84 1.03 0.49 0.00 0.00
Days Sales Outstanding (DSO)		 55.08 80.36 73.53 89.23 80.01 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 538.47 606.20 570.98 524.41 708.39 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 611.82 597.86 308.53 229.73 486.24 393.44 434.46 354.05 738.64 0.00 0.00
Cash Conversion Cycle (CCC)		 -18.27 88.71 335.99 383.91 302.16 -393.44 -434.46 -354.05 -738.64 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.65 2.19 0.22 6.25 5.24 -9.33 -5.13 -5.43 -9.39 -6.87 -7.06
Invested Capital Turnover		 -2.73 -15.90 -14.67 9.81 32.66 -7.77 -8.80 35.08 -3.45 0.00 0.00
Increase / (Decrease) in Invested Capital		 11 7.38 3.69 7.39 8.89 -12 -5.36 -12 -15 2.47 -1.92
Enterprise Value (EV)		 -59 -31 -43 -12 31 -148 -89 -73 -32 40 37
Market Capitalization		 50 57 36 51 78 83 88 90 114 163 226
Book Value per Share		 $4.29 $3.68 $3.21 $2.80 $2.13 $4.74 $3.65 $3.33 $2.89 $2.46 $3.70
Tangible Book Value per Share		 $4.29 $3.68 $3.21 $2.80 $2.13 $4.74 $3.65 $3.33 $2.89 $2.46 $3.70
Total Capital		 105 90 79 69 52 222 172 157 136 116 183
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -109 -88 -79 -63 -47 -231 -177 -163 -146 -123 -190
Capital Expenditures (CapEx)		 0.82 0.74 0.54 0.19 0.19 0.55 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -5.57 -7.71 -1.12 -3.02 -11 -7.29 -7.41 -11 -8.55 -8.64
Debt-free Net Working Capital (DFNWC)		 98 83 71 62 44 220 170 155 134 114 181
Net Working Capital (NWC)		 98 83 71 62 44 220 170 155 134 114 181
Net Nonoperating Expense (NNE)		 3.87 4.63 3.67 3.16 5.01 -88 14 4.06 5.83 5.73 3.96
Net Nonoperating Obligations (NNO)		 -109 -88 -79 -63 -47 -231 -177 -163 -146 -123 -190
Total Depreciation and Amortization (D&A)		 -0.44 -0.37 -0.34 -0.26 -0.14 0.08 0.02 -0.71 -0.83 -0.35 -0.36
Debt-free, Cash-free Net Working Capital to Revenue		 -43.75% -23.38% -32.37% -4.46% -11.64% -38.60% -33.73% -51.52% -156.80% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 403.18% 346.89% 297.51% 245.32% 170.16% 793.30% 786.79% 1,078.89% 1,882.35% 0.00% 0.00%
Net Working Capital to Revenue		 403.18% 346.89% 297.51% 245.32% 170.16% 793.30% 786.79% 1,078.89% 1,882.35% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.60) ($0.68) ($0.54) ($0.46) ($0.68) $1.84 ($0.76) ($0.26) ($1.15) ($0.32) ($0.20)
Adjusted Weighted Average Basic Shares Outstanding		 26.92M 26.98M 27.01M 27.04M 27.03M 39.64M 69.08M 69.20M 61.89M 69.24M 82.89M
Adjusted Diluted Earnings per Share		 ($0.60) ($0.68) ($0.54) ($0.46) ($0.68) $1.83 ($0.76) ($0.26) ($1.14) ($0.32) ($0.20)
Adjusted Weighted Average Diluted Shares Outstanding		 26.92M 26.98M 27.01M 27.04M 27.03M 39.93M 69.08M 69.20M 61.89M 69.24M 82.89M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 24.55M 24.55M 24.61M 24.65M 46.78M 47.11M 47.13M 47.13M 47.20M 49.45M 57.01M
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -14 -11 -7.54 -13 -11 -38 -14 -17 -16 -13
Normalized NOPAT Margin		 -196.01% -255.15% -176.55% -104.58% -183.23% -149.09% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -257.18% -341.66% -236.01% -173.96% -252.42% 1,021.92% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -310.74 -336.43 -268.72 -353.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -217.54 -235.49 -188.08 -247.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -325.05 -349.17 -278.05 -357.95 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -231.86 -248.23 -197.41 -252.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 17.46% 0.00% 0.00% -27.31% -0.69% -7.08%

Financials Breakdown Chart

Key Financial Trends

Whitehawk Therapeutics (NASDAQ:WHWK) remains a development-stage company with no current operating revenue. Revenue was $7.2 million in the third quarter of 2024 and $7.1 million in the first quarter of 2025, but reported revenue fell to zero in the second quarter of 2025 and remained at zero through the second quarter of 2026. The company has therefore relied primarily on capital markets and investment income to fund operations.

Net losses have remained substantial but improved sequentially. Whitehawk reported a net loss of $16.6 million in the second quarter of 2026, compared with losses of $22.2 million in the first quarter of 2026 and $23.3 million in the fourth quarter of 2025. Research and development expense declined to $12.9 million from $17.2 million in the prior quarter, while selling, general and administrative expense fell to $5.2 million from $6.3 million.

Cash generation remains a significant concern. Operating cash flow was negative $14.5 million in the second quarter and negative $22.2 million in the first quarter. However, a $87.5 million common-stock issuance more than offset operating and investing outflows, producing a $50.4 million increase in cash during the quarter. This improvement in liquidity was primarily financing-driven rather than the result of profitable operations.

As of June 30, 2026, Whitehawk held $84.2 million in cash and $104.7 million in short-term investments, or approximately $189.0 million in highly liquid assets. Current liabilities were only $11.1 million, and the company reported no noncurrent liabilities. This provides a strong near-term balance-sheet cushion, although continued losses and potential future clinical spending could materially reduce that cushion.

  • Strong liquidity: Cash and short-term investments totaled approximately $189.0 million at the end of the second quarter of 2026, compared with $73.6 million at the end of the third quarter of 2024.
  • Low leverage: Total liabilities were $11.1 million, with no noncurrent debt reported, limiting interest and refinancing risk.
  • Sequential loss improvement: The quarterly net loss narrowed to $16.6 million from $22.2 million in Q1 2026 and $23.3 million in Q4 2025.
  • Lower operating expenses: Combined research and development and SG&A expense declined to $18.1 million in Q2 2026 from $23.5 million in Q1 2026.
  • Investment income provides some support: Interest and investment income increased to $1.5 million in Q2 2026 from $1.3 million in Q1 2026, partially offsetting operating losses.
  • Funding runway is meaningful but uncertain: The current liquid-asset balance could support operations for several quarters at recent operating cash-burn levels, but the burn rate may change as development programs advance.
  • Investment portfolio activity is substantial: The company purchased $50.6 million and sold or received maturities of $33.8 million in investments during Q2 2026, indicating active cash management rather than operating cash generation.
  • No operating revenue: Whitehawk reported zero revenue in Q2 2026 and has not demonstrated a recurring commercial revenue stream in the latest quarters.
  • Persistent operating cash burn: Operating cash flow has remained negative in every reported quarter in the provided period, including negative $14.5 million in Q2 2026.
  • Dependence on equity financing: The $87.5 million stock issuance was the primary reason cash increased during Q2 2026, creating dilution risk and signaling that internal operations are not funding the business.

Overall, Whitehawk’s balance sheet is substantially stronger than its income statement. The company has ample liquidity, minimal liabilities and a recent reduction in quarterly expenses, but it continues to lose money, generate negative operating cash flow and report no meaningful revenue. For investors, the key financial milestones are sustained reductions in cash burn, progress toward revenue generation and whether future capital raises can be avoided or completed without significant shareholder dilution.

10/16/26 03:46 AM ETAI Generated. May Contain Errors.

Aadi Bioscience Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Aadi Bioscience's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Aadi Bioscience's net income appears to be on a downward trend, with a most recent value of -$20.60 million in 2025, falling from -$31.44 thousand in 2015. The previous period was -$63.69 million in 2024.

Aadi Bioscience's total operating income in 2025 was -$114.40 million, based on the following breakdown:
  • Total Gross Profit: $6.39 million
  • Total Operating Expenses: $120.79 million

Over the last 10 years, Aadi Bioscience's total revenue changed from $0.00 in 2015 to $7.15 million in 2025, a change of 714,500,000.0%.

In the past 11 quarters, Aadi Bioscience's cash and equivalents has ranged from $30.54 million in Q3 2024 to $227.57 million in Q1 2025, and is currently $85.23 million as of their latest financial filing in Q2 2026.

Aadi Bioscience had total debt of $0.00 at the end of 2025, compared with none in 2024, and a 100.0% decrease since 2015.

Over the last 10 years, Aadi Bioscience's book value per share changed from -0.04 in 2015 to 2.89 in 2025.


Related Companies

Financial statements for NASDAQ:AADI last updated on 8/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
I have publicly predicted six major American crashes, before each one happened.
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...
Weiss Ratings | Sponsoredtc pixel
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Undiscovered Sub-$1 Gold-Silver Royalty Stock Takes Flight
A small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...
Digest Publishing | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
INSANE DRONE FOOTAGE
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...
Paradigm Press | Sponsoredtc pixel
A simple options strategy that changed one trader's path
Ian Cooper went from a financially stressed, struggling journalist to a trader who discovered a repeatable opt...
TradeWins | Sponsoredtc pixel